Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Dynavax Technologies Stock Is Soaring Today

By Cory Renauer - Sep 22, 2021 at 12:42PM

Key Points

  • Dynavax Technologies' collaboration partner reported pivotal trial results with a COVID-19 vaccine that uses a proprietary adjuvant to make it more effective.
  • During the successful 30,000-person study, zero severe cases of COVID-19 were reported among volunteers randomized to receive the vaccine.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A COVID-19 vaccine candidate that employs the company's adjuvant technology produced positive clinical trial results.

What happened

Shares of Dynavax Technologies ( DVAX -10.41% ) are on the move after the company's vaccine adjuvant was featured in a positive clinical trial readout. Investors excited about the results have pushed the biotech stock 26.6% higher as of 12:02 p.m. EDT on Wednesday. 

So what 

Today, Dynavax's collaboration partner, Clover Biopharmaceuticals, reported positive results from the pivotal Spectra trial with Clover's COVID-19 vaccine candidate, SCB-2019. This is a protein-based vaccine that employs a booster, or adjuvant, from Dynavax. 

Happy person raises hands in triumph.

Image source: Getty Images.

The Spectra trial enrolled over 30,000 adults in five countries spread across four continents. Clearly, delta and other variants of concern had already taken over when the trial enrolled volunteers. None of those who tested positive were infected with the original virus responsible for COVID-19.

Against the delta variant, SCB-2019 was 79% effective against COVID-19 of any severity. The stock would have risen much further, but overall efficacy was only 67% against COVID-19 infection of any variety.

Now what

Dynavax investors shouldn't be too disappointed with the relatively low overall efficacy rate. The more established vaccines from Moderna and Pfizer were tested before today's variants of concern had taken over. 

The Spectra trial with SCB-2019 is sponsored by the Coalition for Epidemic Preparedness Innovations, or CEPI. This is one of the entities behind the Covax initiative to expand vaccine access worldwide. 

There's a good chance that Covax will pick up what Dynavax and Clover are putting down. None of the volunteers randomized to receive SCB-2019 were hospitalized or died from any COVID-19 variant.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$13.17 (-10.41%) $-1.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.